Opus Genetics, Inc. (IRD) Revenue History
Annual and quarterly revenue from 2019 to present
IRD Revenue Over Time (2019–2025)
IRD Revenue Growth History
2 of 4 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- +6665.7%
- FY2023 revenue growth
- -52.2%
- FY2024 revenue growth
- -42.3%
- FY2025 revenue growth
- +29.1%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $2.2M | -50.6% |
| Q4 2025 | $3.9M | -10.2% |
| Q3 2025 | $3.1M | -20.4% |
| Q2 2025 | $2.9M | +159.2% |
| Q1 2025 | $4.4M | +155.4% |
| Q4 2024 | $4.3M | +154.4% |
| Q3 2024 | $3.9M | -67.6% |
| Q2 2024 | $1.1M | -69.7% |
Multi-year avg. share of annual revenue by fiscal quarter
IRD Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 21, 2026, Opus Genetics, Inc. (IRD) generated trailing twelve-month (TTM) revenue of $12.0 million, reflecting significant decline in growth of -50.6% year-over-year. The most recent quarter (Q1 2026) recorded $2.2 million in revenue, down 44.2% sequentially.
Historical Growth Trajectory
IRD's historical revenue data shows a 3-year CAGR of -29.1%. Opus Genetics, Inc.'s highest annual revenue of $39.9 million was recorded in 2022.
Peer Comparison
Compared to Healthcare sector peers — including JANX (+131.5% YoY), KRYS (+25.1% YoY), and EDIT (+8.0% YoY) — IRD has underperformed the peer group in revenue growth. Compare IRD vs JANX →
IRD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IRDCurrent | $12M | -50.6% | - | -271.9% | |
 JANX | $10M | +131.5% | - | -1576.7% | |
 KRYS | $389M | +25.1% | - | 41.5% | |
 EDIT | $41M | +8.0% | -14.9% | -245.2% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% |
IRD Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $14.2M | +29.1% | $14.2M | 100.0% | $-38,599,000 | -271.9% |
| 2024 | $11.0M | -42.3% | $11.0M | 100.0% | $-62,074,000 | -564.7% |
| 2023 | $19.0M | -52.2% | $19.0M | 100.0% | $-10,563,000 | -55.5% |
| 2022 | $39.9M | +6665.7% | $39.9M | 100.0% | $18.2M | 45.7% |
| 2021 | $589K | - | $589K | 100.0% | $-22,705,000 | -3854.8% |
| 2020 | $0 | - | $0 | - | $-19,968,000 | - |
| 2019 | $0 | - | $0 | - | $-4,193,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
IRD — Frequently Asked Questions
Quick answers to the most common questions about buying IRD stock.
Is IRD's revenue growth accelerating or slowing?
IRD revenue is declining -50.6% year-over-year. TTM revenue fell to $12M, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is IRD's revenue history from 2019 to 2026?
Opus Genetics, Inc. (IRD) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $12M, growing at -50.6% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is IRD's long-term revenue growth rate (CAGR)?
Opus Genetics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -50.6% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for IRD.
Why does IRD's quarterly revenue fluctuate?
IRD quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Opus Genetics, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is IRD's revenue distributed by segment?
IRD reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does IRD's revenue compare to industry peers?
Opus Genetics, Inc. (IRD) with TTM revenue of $12M and -50.6% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.